Aclaris Therapeutics (ACRS) shares Q3 and nine‑month 2025 results

Rhea-AI Filing Summary

Aclaris Therapeutics, Inc. furnished an 8-K to share its latest financial update. The company issued a press release announcing financial results for the quarter and nine-month period ended September 30, 2025. This update is provided to keep investors informed about recent operating performance and financial condition.

The press release is attached as Exhibit 99.1 and is furnished rather than filed, which means it is not automatically incorporated into other SEC reports unless specifically referenced. The 8-K is signed on behalf of the company by Chief Financial Officer Kevin Balthaser.

0001557746false00015577462025-11-062025-11-06

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 6, 2025

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware	​	001-37581	​	46-0571712
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: 

Title of Each Class:		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock, $0.00001 par value		ACRS		The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02 Results of Operations and Financial Condition.

​

On November 6, 2025, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report.

​

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

​

Item 9.01 Financial Statements and Exhibits.

​

(d) Exhibits

​	​	​
Exhibit	​
Number	​	Exhibit Description
99.1	​	Press Release, dated November 6, 2025.
104	​	The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on November 6, 2025, formatted in Inline XBRL.

​

​

​

2

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

	​	​
​	​	ACLARIS THERAPEUTICS, INC.
​	​	​
Date: November 6, 2025	By:	/s/ Kevin Balthaser
	​	Kevin Balthaser Chief Financial Officer

​

​

​

3

FAQ

What did Aclaris Therapeutics (ACRS) disclose in this 8-K?

Aclaris Therapeutics furnished an update announcing its financial results for the quarter and nine months ended September 30, 2025, via a press release attached as Exhibit 99.1.

Which period do the Aclaris Therapeutics (ACRS) results cover?

The results cover the quarter and nine-month period ended September 30, 2025, as stated in the company’s press release.

How did Aclaris Therapeutics provide its Q3 2025 results to investors?

The company issued a press release dated November 6, 2025, announcing its financial results, and furnished that release as Exhibit 99.1 to this 8-K.

Is the Aclaris Therapeutics Q3 2025 press release considered filed with the SEC?

No. The company specifies that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other filings.

Who signed the Aclaris Therapeutics (ACRS) 8-K for the Q3 2025 results?

The report was signed on behalf of Aclaris Therapeutics, Inc. by its Chief Financial Officer, Kevin Balthaser, dated November 6, 2025.

What exhibits are included with this Aclaris Therapeutics 8-K?

The 8-K includes Exhibit 99.1, the press release dated November 6, 2025, and Exhibit 104, the cover page formatted in Inline XBRL.